AI Chips Today - NVIDIA and Silvaco Partner to Elevate Semiconductor Design

NVIDIA Corporation

NVIDIA Corporation

NVDA

0.00

Recent developments in AI chips have been highlighted by a collaboration between Silvaco and NVIDIA to advance digital twin technology in semiconductor design and manufacturing. Silvaco is leveraging NVIDIA's AI and accelerated computing capabilities to integrate high-fidelity, physics-based simulations into its process, enabling faster and more accurate modeling, optimization, and validation of complex semiconductor systems. The partnership aims to capitalize on GPU-accelerated physics simulations and AI-driven surrogate modeling to shorten simulation cycles and enhance design precision. This synergy is set to transform semiconductor technology workflows by improving visualization, collaboration, and efficiency across global engineering teams.

  • NVIDIA (NasdaqGS:NVDA) last closed at $206.84 down 0.9%.

Elsewhere in the market, CXMT (SHSE:688825) was a notable mover up 465.8% and ending trading at CN¥49.00. At the same time, Disco (TSE:6146) softened, down 12.3% to end the day at ¥60,890. Last week, Disco appointed Andre Mintz to its Board of Directors, enhancing its expertise with his extensive background in security and privacy risk management.

Best AI Chip Stocks

  • Broadcom (NasdaqGS:AVGO) finished trading at $381.92 down 2.7%.
  • Advanced Micro Devices (NasdaqGS:AMD) finished trading at $521.95 down 3.3%. On Friday, the company announced an expanded collaboration with VAST Data to enhance AI infrastructure capabilities using its 6th Gen EPYC CPUs and Instinct GPUs.
  • Micron Technology (NasdaqGS:MU) ended the day at $920.95 down 7.0%.

Key Takeaways

  • Reveal the 114 hidden gems, such as Advanced Micro-Fabrication Equipment China, ACM Research (Shanghai) and MediaTek, among our AI Chip Stocks screener with a single click here.
  • Searching for a Fresh Perspective? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Sources: